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Abstract:  Plant-based  platforms  have  been  successfully  applied  for  the  last  two  
decades  for  the  efficient  production  of  pharmaceutical  proteins.  The  number  of 
commercialized  products  biomanufactured  in  plants  is,  however,  rather  discouraging. 
Cytokines are small glycosylated polypeptides used in the treatment of cancer, immune 
disorders and various other related diseases. Because the clinical use of cytokines is limited 
by high production costs they are good candidates for plant-made pharmaceuticals. Several 
research groups explored the possibilities of cost-effective production of animal cytokines 
in plant systems. This review summarizes recent advances in this field. 
Keywords: cytokines; pharmaceutical proteins; plant-based production systems; molecular 
farming; interleukins; transgenic plants 
 
1. Introduction 
Development of DNA recombination and plant transformation techniques resulted in creating the 
novel protein production platforms based on either whole plants or plant cells. The results of the first 
experiments describing the plant-based production of pharmaceutical proteins were published about 
25 years ago. The successful production of the human growth hormone in tobacco and sunflower [1] 
and of albumin in tobacco and potato [2] indicated that plant-based production systems might be used 
for  the  production  of  mammalian  proteins.  The  process  of  using  plant-based  systems  as  highly 
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effective production platforms for the molecules with biotechnological (industrial or pharmaceutical) 
significance  is  named  molecular  farming,  while  the  pharmaceutical  products  obtained  in  the  
plant-based systems are often called plant-made pharmaceuticals (PMPs). At present, a list of PMPs in 
various stages of development or potential commercialization is quite extensive and includes various 
antibodies  and  their  fragments,  vaccine  antigens,  blood  substitutes,  enzymes,  cytokines  and  other 
important and valuable proteins. Multiple examples of such proteins and the extensive evaluation of 
the advantages and disadvantages of various plant-based platforms for the expression of the particular 
targets can be found in many recent reviews (for example, [3], see also below), therefore this work is 
limited only to a small group of PMPs, the cytokines. 
2. Cytokines and Their Therapeutic Application 
Cytokines are small polypeptides, proteins or glycoproteins involved in the regulation of processes 
as diverse as proliferation, differentiation and mobility of cells. Cytokines are important components of 
the immune system; however they also participate in embryogenesis, affect the hematopoietic system 
and act on neuronal cells. The anatomic and structural distinctions between hormones and cytokines 
are unclear and cytokines are sometimes named the hormones of immune system. They can have an 
affect  not  only  on  cells  in  the  close  proximity  but  also  those  in  distant  organs.  Cytokines  
are  characterized  by  a  considerable  complexity  of  actions  such  as  redundancy,  pleiotropy, 
multifunctionality, synergistic or antagonistic effects and cascades of positive or negative feedbacks. 
At present, more than 100 different cytokines are known. Several methods of division of this large 
family into subgroups have been used. The most convenient seems to be functional categorization 
according to KEGG (Koto Encyclopedia of Genes and Genomes [4]). As shown in Figure 1, at least 
8 families  can  be  distinguished:  Class  I  cytokines  (hematopoietin  family),  Class  II  cytokines 
(interferons/IL-10  family),  platelet-derived  growth  factors  (PDGF),  tumor  necrosis  factors  (TNF 
family), IL-1 family, IL-17 family, tumor growth factor family (TGF-beta family) and chemokines. 
For  more  information  about the cytokines the  reader is referred to the Cytokines &  Cells Online 
Pathfinder Encyclopedia (COPE) [5]. 
An imbalance in cytokine production or signaling contributes to various pathological immune and 
inflammatory disorders. In addition, plasma levels of various cytokines may give information on the 
presence, or even predictive value of inflammatory processes involved in autoimmune diseases such as 
rheumatoid arthritis. The biological role of cytokines and their dual (immunosuppressive as well as 
immunostimulatory) properties are a strong indication for multiple clinical applications. A number of 
recombinant cytokines have been approved for clinical use (Table 1) and multiple cytokine therapies 
are  in  clinical  trials  [6–8].  Not  only  the  cytokines  but  also  cytokine  receptors,  antagonists  of  the 
cytokine receptors and the relevant specific antibodies can be used in therapy [8]. Significant numbers 
of cytokines have been tested as potential adjuvants of immunological response, particularly during 
mucosal  immunizations,  such  as  oral,  intranasal  and  intravaginal  [2,9].  Granulocyte-macrophage 
colony stimulating factor (GM-CSF) seems to e one of the best candidates for PMP because it is 
relatively stable, consists of one kind of polypeptide, i.e., it is encoded by one gene, and, essentially, it 
is well tolerated by the patients. Numerous new implications of this cytokine have been proposed and 
tested in preclinical and clinical trials, including the combined application of GM-CSF and IL-2 as Int. J. Mol. Sci. 2011, 12                       
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adjuvants in cutaneous melanoma along with autologous vaccine [10]. However, it is necessary to 
mention that the use of cytokines as adjuvants in vaccines is considered controversial because they can 
sometimes have serious side effects such as vascular leak syndrome [11]. An interesting idea is the 
production and application of ―fusokines‖, hybrid molecules generated after cloning and fusing two 
separate cytokine encoding cDNAs into a single open reading frame, however these experiments have 
been limited to the murine experimental models [12]. 
Figure 1. The families of cytokines (according to the Kyoto Encyclopedia of Genes and 
Genomes [4]). 
 
Table 1. Examples of cytokines approved for use in humans. Modified from [7,8]. 
Cytokine   Disease or Indication  Drug Name (Company) 
G-CSF  Neutropenia  Neupogen/Filgrastim (Hoffmann-La Roche) 
GM-CSF 
Leukemia 
Bone marrow 
Stem cell transplants 
Leukine/Sargramostin (Bayer) Int. J. Mol. Sci. 2011, 12                       
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Table 1. Cont. 
Cytokine   Disease or Indication  Drug Name (Company) 
Interferon-α (INF-α) 
Chronic hepatitis B 
Chronic hepatitis C 
Hairy cell leukemia 
Chronic myeloid leukemia 
Condyloma acuminate 
AIDS-related Kaposi’s sarcoma 
genital warts 
Intron A (Schering Plough) 
Roferon A (Hoffman La Roche) 
Infergen (Three Rivers Pharmaceuticals) 
Alferon N (HEMISPHERx Biopharma) 
Pegasys (Genentech USA/Roche) 
Pegintron (Merck) 
Interferon-β (INF-β)  Relapsing multiple sclerosis 
Betaseron (Bayer) 
Avonex (Biogen Idec) 
Interferon-γ (INF-γ) 
Malignant osteopetrosis 
Chronic granulomatous disease  
Actimmune (Intermune Pharma) 
Erythropoietin-α 
(EPO-α) 
Anemia due to chronic renal failure 
HIV infected patients 
Chemotherapy 
Primary bone marrow disorders 
Eprex (Cilag Jansen) 
Epogen (Amgen) 
Procrit (Ortho Biotech) 
IL-2 
Metastatic renal cell cancer 
Metastatic melanoma 
Aldesleukin (Novartis) 
Proleukin (Prometheus Laboratories) 
IL-11  Thrombocytopenia 
Oprelvekin/Neumega (Genetics Institute, Inc./ 
Wyeth/Pfizer)  
3. Recombinant Cytokines from Plant-Based Platforms 
Plant-based production of recombinant cytokines is an emerging area and most previous research 
has concentrated on a few well-characterized cytokines. Some most interesting examples from the list 
shown in Table 2 are briefly discussed below. 
3.1. Hematopoietin Family 
Erythropoietin was one of the first cytokines produced in plant cells [13]. The cDNA encoding 
human erythropoietin was expressed from the 35S promoter of cauliflower mosaic virus (CaMV) in 
the tobacco BY2 cells. The signal peptide at the N-terminus was intended to enable the extracellular 
secretion of the recombinant protein. The secretion was observed in the protoplasts cultures, while in 
the cell cultures erythropoietin was translocated though the cellular membrane but it stayed bound by 
the cell wall and was not secreted into the medium. Most probably, the size of 30 kDa was too large 
for free migration through the cell wall. The protein is glycosylated in animal cells, so was examined 
in plant cells, however the pattern and length of the sugar chain were different. Unfortunately, only a 
low yield (0.0026% of total soluble protein [TSP]) was achieved. The protein was biologically active 
in vitro but not in vivo. The possible explanation for this might be the difference in glycosylation, 
which is known to affect the protein stability in blood.  Int. J. Mol. Sci. 2011, 12                       
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Table  2.  Examples  of  cytokines  produced  in  plant-based  systems.  Different  expression  systems  are  marked  differently  (no  
background-suspension  cultures;  light  grey-transgenic  or  transplastomic  plants;  dark  grey-plant  virus-based  production);  nos-nopaline 
transcriptional  terminator,  MUbi-1  i  Scubi-9-polyubiquitin  promoters;  *  Method  of  transformation:  T-Agrobacterium-mediated;  
M-microbombardment, V-viral vector, L-lipofectin-mediated transformation of protoplasts. The examples concern human cytokines unless 
indicated otherwise. 
Cytokine  * Method/Plant Material  Selected Elements of the Expression Cassette  Expression Level/Yield  Reference 
erythropoietin  T/tobacco (BY2) cells 
suspension  
35S promoter and terminator  0.0026% TSP; 25 pg/L  [13] 
G-CSF   T/tobacco cells suspension   35S promoter with the double enhancer, Ω-translation enhancer; 
nos terminator 
105 μg/L  [14] 
GM-CSF  T/tobacco cells suspension   35S promoter, translation enhancer from TEV, His tag,  
T7 terminator 
150 µ g/L (intercellular); 250 µ g/L 
(secretory)  
[15] 
GM-CSF   T/tobacco cells suspension   35S promoter with the double enhancer, nos terminator  180–780 µ g/L  [16] 
GM-CSF   M/rice cells suspension   rice amylase promoter and signal peptide  129 mg/L 
(25% secreted proteins)  
[17] 
GM-CSF  M/rice cells suspension  rice amylase promoter and signal peptide, RNAi-mediated 
silencing of α-amylase gene to 8.2% 
280 mg/L  [18] 
GM-CSF  M/rice cells suspension   rice amylase promoter and signal peptide, RNAi-mediated 
silencing of cysteine proteinase 
290 mg/L  [19] 
GM-CSF  M/rice cells suspension  rice amylase promoter and signal peptide; co-expression  
of gene encoding synthetic protease inhibitor (SPI-II) 
250 mg/L  [20] 
GM-CSF  M/sugarcane leaves   MUbi-1 promoter from maize or SCubi-9 from sugarcane  0.02% TSP  [21] 
GM-CSF   T/tobacco seeds  Gt1, Gt3 (glutelin) promoters and signal peptide,  
nos terminator 
0.005–0.03% TSP 
 
[22] 
GM-CSF  T/tobacco seeds  Gt1 (glutelin) promoter and signal peptide, nos terminator  1.3% TSP  [23] 
GM-CSF  T/rice seeds  Gt13a (glutelin) promoter (specific for seed endosperm) and 
glutelin signal peptide, nos terminator, codon optimalization 
0.5–14 μg/seed  [24] 
Murine GM-CSF  T/tobacco leaves  RbcS1 Promoter; signal peptide, KDEL  19 µ g/g fresh leaves; 0.22%  [25] Int. J. Mol. Sci. 2011, 12                       
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Table 2. Cont. 
Cytokine  * Method/Plant Material  Selected Elements of the Expression Cassette  Expression Level/Yield  Reference 
GM-CSF   V/N. benthamiana leaves  PVX-derived vector: 35S promoter, His tag  0.2–2% TSP  [26] 
IL-2   T/tobacco cells suspension   35S promoter, T7 terminator  0.09 mg/L  [27] 
IL-2  T/potato tubers   patatin promoter; nos terminator  115 U/mg TSP  [28] 
Murine IL-2  T/Arabidopsis seeds 
T/tobacco seeds 
novel binary Gateway vector (pPphasGW) containing  
β-phaseolin promoter from common bean and the signal peptide 
of the Arabidopsis 2S2 seed storage protein gene; KDEL 
Much higher yield in Arabidopsis 
than in tobacco: 0.3 mg/g of seeds 
(0.7% TSP); biologically active  
in vitro 
[29] 
IL-4  T/tobacco leaves   35S promoter with double enhancer, t-CUP-translation 
enhancer, ELP, KDEL, nos terminator  
0.086% TSP  [30] 
IL-4  T/tobacco leaves,  
T/potato tubers  
35S promoter, KDEL sequence  0.1% TSP in tobacco;  
0.08% TSP in potato 
[31] 
IL-4  T/tobacco cells suspension   35S CaMV promoter, T7 terminator  0.45 mg/L  [27] 
IL-10   T/tobacco leaves   35S promoter with double enhancer, t-CUP-translation 
enhancer, ELP, KDEL, nos terminator 
0.27% TSP  [30] 
IL-10  T/tobacco leaves   (A) promoter 35S CaMV, with or without His tag,  
chloroplast leader peptide 
(B) promotor 35S CaMV, His tag; mitochondria  
leader peptide 
(A) 7 ng/mg TSP (without His);  
43 ng/mg TSP (with His) 
(B) no accumulation 
[32] 
IL-10  T/rice seeds   GluB-1 promoter and signal peptide, His tag, KDEL, 
codon optimization 
2 mg of pure IL-10 per 40 g  
of rice powder 
[33] 
IL-10  T/tobacco leaves  35S promoter with double enhancer; three constructs for each 
viral IL-10 or murine IL-10, ER-targeted, plasma membrane 
(IL-10 facing the apoplast), ER-membrane (IL-10 facing the 
cytosol) assayed in transient expression system, cassettes for 
ER-targeted cytokines were used for the stable expression 
Viral: 10.8 µ g/g fresh leaves 
Murine: 37.0 µ g/g fresh leaves 
[34] 
IL-12  T/tobacco leaves   35S promoter and terminator  40 ng/g  [35] Int. J. Mol. Sci. 2011, 12                       
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Table 2. Cont. 
Cytokine  * Method/Plant Material  Selected Elements of the Expression Cassette  Expression Level/Yield  Reference 
IL-12  T/tomato leaves and fruits   35S promoter with double enhancer; 35S terminator  7.3 μg/g leaves 
4.3 μg/g fruits 
[36,37] 
IL-12  T/tobacco cells suspension   35S promoter with double enhancer; Ω-translation enhancer  175 μg/L  [38] 
IL-13  T/tobacco leaves   double 35S promoter; translation enhancer from AMV; KDEL; 
nos terminator 
0.15% TSP  [39] 
IL-18  T/tobacco leaves   35S promoter with double enhancer, Ω-translation enhancer, 
nos terminator 
0.004–0.051% TSP; 351 ng/g  [40] 
cardiotrophin-1  M/tobacco leaves, chloroplasts 
transformation 
(A) promotor rrn (promoter 16S RNA), translation enhancer 
(5’UTR/leader sequence of the phage T7 gene 10) 
(B) psbA promoter and translation enhancer (5’UTR psbA) 
(A) 0.14 mg/g leaves 
(B) up to 1.14 mg/g leaves  
[41] 
IFN-α2b  
IFN-α8 
T/potato  -  560 IU/g of tissue  [42] 
IFNα  L/tomato (leaf tissue and  
cells suspension) 
P1 portion of the dual ―bi-directional‖ promoter from 
A. tumefaciens cDNA, polyadenylation signal from 
A. tumefaciens gene-7 
923–3029 U/g FW tissue  [43] 
IFN-α2  V/squash (Cucurbita pepo) and 
cucumber (Cucumis sativus) 
Viral vector dirived from attenuated zucchini yellow mosaic 
potyvirus (AG) 
max. 430,000 IU/FW of leaves  [44] 
IFN-α2b  M/tobacco leaves, chloroplasts 
transformation 
Cassette: 5’UTR/HIS/THR/IFNα2b cloned into the chloroplast 
vector pLD-CtV 
3 mg/g, 20% TSP  [45] 
IFN-α2b   T/carrot leaves  (A) 35S promoter, nos terminator, calreticulin apoplast  
targeting signal  
(B) taproot-specific Mll promoter, nos terminator, calreticulin 
apoplast targeting signal 
Biological activity on average:  
(A) 26.8 ×  10
3 U/g FW of young 
leaves 
(B) 8.56 ×  10
3 U/g FW of roots 
[46] 
IFNβ  transient, agroinfiltration of the 
leaves of lettuce 
35S promoter, nos terminator  3.1 ×  10
4 IU/mL  [47] Int. J. Mol. Sci. 2011, 12                       
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Table 2. Cont. 
Cytokine  * Method/Plant Material  Selected Elements of the Expression Cassette  Expression Level/Yield  Reference 
IFNγ  T/rice cells suspension  (A) constitutive maize ubiquitin promoter, with or without 
αAmy3 leader peptide; His tag;  
(B) sucrose-starvation inducible promoter (rice αAmy3 
promoter); with or without αAmy3 leader peptide; His tag 
(A) 11.1 ng/mL (secretory) and 
699.79 ng/g cell (intracellular) 
(B) 17.4 ng/mL media (secretory) 
and 131.6 ng/g cell (intracellular) 
[48] 
Chicken IFN-α  Transient expression, 
agroinfiltration of the  
leaves of lettuce 
35S promoter, nos terminator  0.393 μg/kg tissue, 0.0004% TSP  [49] 
Fish IFN- α1  T/rice 
T/potato 
35S promoter with double enhancer, nos terminator 
 
Biological activity: 
in rice-up to 0.82 U/mg leaves; 
in potato-up to 5.4 U/mg leaves 
[50] 
TNF-α  
 
T/potato  35S promoter, Ω-translation enhancer, SEKDEL sequence  15 µ g/g tissue  [51] 
Fibroblast growth 
factor 8 isoform b 
(FGF8b) 
T/tobacco leaves  35S promoter with double enhancer; 35S terminator ,c-myc, 
His, KDEL 
4.1% TSP  [52] 
Insulin like growth 
factor 1 (IGF-1) 
M/tobacco, transplastomic  psbA promoter, translantion enhancer (5’UTR psbA)  
and ZZ-tag from S. aureus, codon optimization 
up to 32% TSP  [53] 
Insulin like growth 
factor 1 (IGF-1) 
M/rice seeds  Glutelin (Gt13a) promoter, the Gt13a signal peptide in  
frame with the fusion protein containing IGF-1 attached  
to the C-terminus of ER luminal binding protein (BipC) ,  
nos terminator 
up to 6.8% of total seed protein; 
biologically active in vivo 
(effectively reduced blood glucose 
in diabetic mice) 
[54] 
 Int. J. Mol. Sci. 2011, 12                       
 
 
3544 
Several independent groups focus on the production of human GM-CSF. Initially, it was produced 
in tobacco [15,16] and rice [17–20] cell suspension cultures. One of the most interesting approaches to 
improve the yield  was the addition of  either mineral  salts or  BSA  to the growth  medium,  which 
stabilized the secreted cytokine [15]. A significant (up to 4-fold) increase of the yield was achieved 
due to the addition of 5% (w/v) gelatin to the medium [16]. However, in cultures older than 4 days, 
gelatin inhibited cell growth, presumably by activation of proteolytic enzymes. Much higher efficiency 
was  achieved  in  cultures  of  rice  cell  suspension,  particularly  with  the  specific  promoter  of  rice 
amylase, Ramy3D [17]. Using this system, a yield of 129 mg/L of culture was achieved in the absence 
of sugar (when this promoter is activated). The system was subsequently optimized in three strategies:  
(i)  silencing  of  the  gene  encoding  a-amylase,  a  dominant  protein  secreted  by  rice  cells  [18]; 
(ii) silencing of the gene encoding cysteine proteinase secreted by the rice cells to the medium [19]; 
and (iii) co-expression of cytokine with the protease inhibitor [20]. Each of these strategies increased 
the yield of recombinant GM-CSF at least two-fold.  
Whole plant platforms were also used for GM-CSF production. The maximal yield in the leaves of 
transgenic sugarcane was about 0.02% [21] and in tobacco leaves about 0.22% of TSP [25]. In the 
seeds  of  transgenic  rice  recombinant  GM-CSF  accumulated  up  to  1.3%  of  TSP  [23].  The  highest 
expression (up to 2%  TSP)  was reported  for the viral vector based  on PVX (potato virus  X)  with 
modified  coat  protein  [26].  In  most  cases  the  biological  activity  of  recombinant  GM-CSF  was 
confirmed in vitro, while in at least in one case it was also verified in vivo in a mouse model [24]. 
The  first  report  about  the  expression  of  recombinant  IL-2  and  IL-4 in  tobacco  cell  suspension 
cultures was published in 1998 [27]. The authors assumed that the presence of intrinsic signal peptide 
would provide an efficient extracellular secretion of recombinant proteins. In fact, most of the cytokine 
produced  was  retained  in  the  cells  and  only  the  secreted  proteins  had  biological  activity.  Other 
strategies include targeting of the recombinant IL-4 proteins into endoplasmic reticulum, using the 
promoter specific to potato tubers or expression as a protein fusion with elastin, however the reported 
yield was never higher than 0.08% for IL-4 [30] or 115 U/g of potato tuber for IL-2 [28]. 
Other  examples  of  cytokines  from  this  group  produced  in  plant-based  platforms  include 
cardiotrophin 1 [41], interleukin 12 [35–38], interleukin 13 [39] and interleukin 18 [40]. Interestingly, 
IL-12 was produced as a multimeric protein at levels exceeding 5% of TSP after coinfiltration of 
Nicotiana benthamiana leaves with two Agrobacterium strains individually encoding each subunit [55]. 
Cardiotrophin 1 was produced in transplastomic tobacco plants with an efficiency of about 5%. In 
addition, it appeared that its biological activity is inhibited by light, which most probably destroys the 
protein conformation [41]. 
3.2. Interferon and IL-10 Family 
Interferons have been frequently selected as candidates for production in plant-based systems. The 
first reports about the plan-based production of human interferon date back to the beginning of the  
90 s [56], however it was the usage of transplanstomic plants that allowed for the huge increase of 
yield,  up  to  20%  of  TSP  [45].  It  is  worth  mentioning  that  not  only  human  interferons  but  also 
interferons from chicken [49] and salmon [50] were successfully produced in plant-based systems. Int. J. Mol. Sci. 2011, 12                       
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In plant-based systems, interleukin 10 was targeted either to chloroplasts or mitochondria, with 
better results for the former organelle [32]. In the case of this cytokine, the best yield of 0.27% TSP 
was achieved after expression of IL-10 in fusion with elastin [30]. 
3.3. Other Families 
The  single  representatives  of  the  other  families  of  cytokine  were  produced  in  plant  systems 
(Table 2). 
Tumor  necrosis  factor (TNF-α),  which  is  a  member  of  the  TNF  family,  has  been  produced  in  
potatoes [51]. The authors used two types of expression cassettes, both containing 35S promoter of 
CaMV  and  the  translation  enhancer  from  TMV.  One  of  the  cassettes  had  additional  sequences 
encoding  the  N-terminal  signal  peptide  and  the  C-terminal  SEQDEL  peptide,  responsible  for  ER 
targeting. However, this strategy did not result in any significant increase of cytokine accumulation.  
In both cases the yield was similar and reached about 15 µ g of biologically active TNF-α per 1 g of  
plant tissue. 
Interleukin  18  belongs  to  the  IL-1  family.  In  this  case,  the  enhanced  35S  promoter  and  the 
translation enhancer from TMV were used; however the yield was moderate, up to 0.05% of TSP [40]. 
Bioactive human fibroblast growth factor 8b (FGF), a member of PDGF family, was produced in 
tobacco plants [52]. The cDNA coding hFGF8b was cloned under control of the double CaMV 35S 
promoter  (CaMV35SS).  In  an  Agrobacterium-mediated  transient  expression  system  after  vacuum 
leaves infiltration the yield of the Ni-NTA affinity chromatography purified proteins c-myc-His tagged 
FGF8b and His-KDEL tagged FGF8b was 2.7% and 4.1% of TSP (90 and 150 µ g/g FW), respectively. 
Another member of the same PDGF family, Insulin-like Growth Factor 1 (IGF-1), was efficiently 
produced in transplastomic plants [53]. Cell proliferation assays in human HU-3 cells demonstrated the 
biological activity of this recombinant protein. 
4. Prospects for Commercialization Plant-Produced Cytokines 
The  successful  introduction  of  plant-produced  recombinant  cytokines  into  the  market  might 
encounter problems similar to those encountered in the commercialization of any other PMPs [57]. 
These problems can be divided into two main categories: (i) technological (such as low yield, poor 
performance  of  the  recombinant  product  or  problems  with  postharvest  bioprocessing)  making  the 
platforms economically uncompetitive and (ii) legal (such as public objections and stringent regulatory 
requirements for open-field cultivation of transgenic plants, high regulatory-approval costs and long 
timelines), which result in a long timeframe-to-market and a lack of interest from the potential investors.  
4.1. Strategies Used to Improve the Performance of Plant-Base Production Platforms 
The researchers dealing with molecular farming issues have always been aware of the needs for 
technological improvement. Various factors limit the yield of PMPs and there are multiple possibilities 
to overcome the yield and economic constrains. These problems have been frequently considered in 
many excellent reviews [58–60]. The concerns generally expressed with regard to PMPs also pertain to 
the plant-produced cytokines. Therefore, we would like to mention briefly only a few strategies, which Int. J. Mol. Sci. 2011, 12                       
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were successfully applied in the case of this type of therapeutics. First of all, some PMPs can be 
produced in edible crops to eliminate the need for purification of the desired products in the case of 
oral application of the recombinant proteins. In addition, several critical elements must be optimized to 
get a high yield of PMP, including the use of tissue specific promoter or optimization of the codons 
within the transgene to match the optimal codons of the host. For example, efficient accumulation 
Insulin-like  Growth  Factor  I  (IGF)  was  achieved  in  transgenic  tobacco  chloroplasts  after  codon 
optimization  of  the  transgene [34,53].  The  native  IGF  gene  (IGF-n)  with  less  than  optimal  for 
chloroplast AT content of 41% or synthetic (IGF-s) gene with optimized 60% AT were cloned into a 
vector  containing  the  psbA  promoter,  5’UTR  (which  enhances  translation  under  illumination)  and 
3’UTR (which increases the stability of the transcript). The IGF-n transgenic plants had an expression 
level of 9.5% TSP. In IGF-s plants, expression level increased to 11.3% TSP, however the expression 
of IGF was increased up to 32% TSP under continuous illumination by the chloroplast light regulatory 
elements. The importance of protein stability is illustrated by other reported cases, where significant 
elevation of the yield was achieved by targeting the PMP into the storage organs such as seeds or 
grains  [22–24,33].  For  example,  a  strong  endosperm-specific  promoter  (Gt13a)  and  rice-preferred 
codons  optimization  improved  the  transcription  and  translation  of  hGM-CSF,  giving  the  yield  of 
14 µ g/seed  [24].  In  this  case  also  a  signal  peptide  that  targeted  recombinant  protein  into  the 
endomembrane  system  of  rice endosperm such  as the ER  and protein bodies was used to protect 
against degradation by proteases. Additionally, it is worth mentioning that accumulation in seeds might 
eliminate the need for low temperature maintenance during transport and long-term storage of PMPs. 
There  are  also  successful  examples  of  fusion  strategies  being  used  to  obtain  the  high  yield  of 
recombinant cytokines in plants, including IGF-1 produced in fusion with the C-terminus of a rice 
luminal binding protein [54]. The appropriately designed fusion, which does not interfere with the 
biological activity of the recombinant proteins, might be a safe and effective oral delivery system for 
cytokins in general.  
Proteomic analysis of the effects of massive over-accumulation of GM-CSF in plants gave us some 
information about the fate of recombinant proteins in plant cells [61]. This work also indicated that the 
presence of recombinant protein might affect the total proteome of grain cells. For example, the major 
endogenous storage proteins, glutelin, globulin and prolamin, and a majority of carbohydrate-related 
proteins were down-regulated, while 26S proteasome-related proteins and molecular chaperons were 
up-regulated in transgenic rice endosperm. The author concluded that over expression of recombinant 
proteins induced unfolded protein response and that overall protein trafficking in rice endosperm was 
affected.  This  work  shows  that  the  influence  of  transgene  expression  on  host  metabolism  is  an 
important issue. 
4.2. Other Problems to Consider 
The initial pictures describing the feasibility of the production of edible plant-made pharmaceuticals 
or vaccines in carrots or bananas appeared somewhat naive. A direct consumption (oral application) of 
plant parts containing recombinant therapeutics might be controversial because of the need to meet the 
existing rigorous regulations concerning consistent composition of medicines for humans. Most legal 
and regulatory issues linked to the commercialization of PMPs were extensively discussed in a number Int. J. Mol. Sci. 2011, 12                       
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of recent reviews [57,62,63] and they will not be repeated here. There are also other problems and 
questions regarding the use of genetically modified plants and their effects on the human health and 
the environment in general. These issues include some concerns regarding ethics, related to the risk of 
transferring transgene (especially antibiotic-resistance markers) from genetically modified plants to the 
environment, gut microflora and pathogenic microbes. As mentioned earlier, the risk of uncontrolled 
spreading of the transgene can be substantially reduced by the strategy of biocontainment or physical 
containment. In addition, using marker-free technology eliminates the risk of transfer of the marker 
genes [64,65]. There are also some religious issues related to the consumption of transgenic plants with 
animal genes introduced into them, especially, for some strict vegetarian people and some ethnical 
groups with certain food preferences and restrictions, but this concern is outside the scope of the 
present review. 
It is necessary to mention that the avoidance of plant cultivation in open areas, applying various 
approaches of containment use and the usage of only isolated (purified) recombinant products lead,  
of course, to more expensive products and limit the direct use of GM plants as edible sources of 
recombinant therapeutics.  
5. Conclusions 
Recent  development  of  knowledge  about  the  immune  system  opens  new  perspectives  for  
the  application  of  cytokines  and  opens  a  potentially  large  market,  however  finding  the  niche  for  
plant-produced recombinant cytokines in the pharmaceutical market might be tough. Many technical 
and  regulatory  challenges  limit  the  availability  of  this  sector  for  the  prospective  investors.  All 
molecular  farming  projects,  including  those  involved  in  the  production  of  therapeutics  for  the 
treatment  of  immune  system  disorders,  must  consider  the  costs  and  feasibility  of  standardization, 
validation and licensing of the potential medical products. The biopharming industry is in a dynamic 
state and many companies involved in plant-based biomanufacturing of recombinant proteins cease to 
exist before the commercialization of any products [57]. Nevertheless, there are now about 20 PMPs, 
including  at  least  one  cytokine  (interferon  α)  in  development  as  potential  products  for  the 
pharmaceutical market [66]. 
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